Effects and mechanism of simvastatin and fenofibrate on the expression of hepatic apolipoprotein M in mice
10.3760/cma.j.issn.1008-1372.2010.11.012
- VernacularTitle:辛伐他汀和非诺贝特对小鼠肝脏载脂蛋白M表达的影响及调控机制
- Author:
Liu YANG
;
Shuiping ZHAO
;
Saidan ZHANG
;
Tie LI
- Publication Type:Journal Article
- Keywords:
Simvastatin/PD;
Procetofen/PD;
Apolipoproteins/ME/DE
- From:
Journal of Chinese Physician
2010;12(11):1474-1477
- CountryChina
- Language:Chinese
-
Abstract:
Objective To examine the effects and mechanisms of simvastatin and fenofibrate, and combination of the two drugs on the expression of apolipoprotein M (apoM). Methods The male C57BL/6N mice ( n =32) were random divided into four groups, including control group (with no special treatment), statin group (with simvastatin [10mg/( kg · d) for 4 weeks], fibrate group (with fenofibrate [100mg/( kg · d) for 4 weeks] and combination group ( with simvastatin [10mg/( kg· d)] and fenofibrate [100mg/( kg · d) for 4 weeks]. The levels of apoMmRNA and protein, hepatic nuclear factor (HNF-1α)mRNA, liver X receptor-α (LXRα) mRNA in mouse liver were measured. Results Both of simvastatin and fenofibrate can increase the expression of apolipoprotein M ( 1.97 ± 0. 04,2. 02 ± 0. 02 ) and HNF-1αmRNA ( 1.74 ± 0. 05,1.71 ± 0. 04). Combination group obtained more effects than either single agent ( P ＜ 0. 05 ). Simvastatin could decrease the expression of LXRα mRNA ( 1.00 ± 0. 02 ) ( P ＜ 0. 05 ). Fenofibrate could increase the expression of LXRα mRNA(2. 80 ±0. 04) ( P ＜0. 05). No significant difference in LXRα expression was seen between combination( 1.56 ±0. 03 ) and control group( 1.53 ±0. 03 )( P ＞0. 05). Conclusions Simvastatin and fenofibrate can increase apoM expression. Treatment with combination of the two drugs is more effective, and the mechanism might be related to the regulation of HNF-1α and LXRα.
